These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 17520819)

  • 21. [Peroxisome proliferator-activated receptor alpha, gamma and the dual agonists and atherosclerosis].
    Chen LH; Yang GR; Guan YF
    Sheng Li Ke Xue Jin Zhan; 2007 Apr; 38(2):153-5. PubMed ID: 17633233
    [No Abstract]   [Full Text] [Related]  

  • 22. Selective partial agonism of liver X receptor alpha is related to differential corepressor recruitment.
    Phelan CA; Weaver JM; Steger DJ; Joshi S; Maslany JT; Collins JL; Zuercher WJ; Willson TM; Walker M; Jaye M; Lazar MA
    Mol Endocrinol; 2008 Oct; 22(10):2241-9. PubMed ID: 18669643
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Liver X receptor and farnesoid X receptor as therapeutic targets.
    Rader DJ
    Am J Cardiol; 2007 Dec; 100(11 A):n15-9. PubMed ID: 18047847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential effects of pharmacological liver X receptor activation on hepatic and peripheral insulin sensitivity in lean and ob/ob mice.
    Grefhorst A; van Dijk TH; Hammer A; van der Sluijs FH; Havinga R; Havekes LM; Romijn JA; Groot PH; Reijngoud DJ; Kuipers F
    Am J Physiol Endocrinol Metab; 2005 Nov; 289(5):E829-38. PubMed ID: 15941783
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Newer therapeutic strategies to alter high-density lipoprotein level and function.
    Bosch N; Frishman WH
    Cardiol Rev; 2014; 22(1):17-24. PubMed ID: 23707991
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging small molecule drugs.
    Colin S; Chinetti-Gbaguidi G; Kuivenhoven JA; Staels B
    Handb Exp Pharmacol; 2015; 224():617-30. PubMed ID: 25523004
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Role of PPAR and Its Cross-Talk with CAR and LXR in Obesity and Atherosclerosis.
    Xu P; Zhai Y; Wang J
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29690611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Basis for improved permeability barrier homeostasis induced by PPAR and LXR activators: liposensors stimulate lipid synthesis, lamellar body secretion, and post-secretory lipid processing.
    Man MQ; Choi EH; Schmuth M; Crumrine D; Uchida Y; Elias PM; Holleran WM; Feingold KR
    J Invest Dermatol; 2006 Feb; 126(2):386-92. PubMed ID: 16374473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The nuclear receptor LXR is a glucose sensor.
    Mitro N; Mak PA; Vargas L; Godio C; Hampton E; Molteni V; Kreusch A; Saez E
    Nature; 2007 Jan; 445(7124):219-23. PubMed ID: 17187055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integration of metabolism and inflammation by lipid-activated nuclear receptors.
    Bensinger SJ; Tontonoz P
    Nature; 2008 Jul; 454(7203):470-7. PubMed ID: 18650918
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Miniaturization of cell-based beta-lactamase-dependent FRET assays to ultra-high throughput formats to identify agonists of human liver X receptors.
    Chin J; Adams AD; Bouffard A; Green A; Lacson RG; Smith T; Fischer PA; Menke JG; Sparrow CP; Mitnaul LJ
    Assay Drug Dev Technol; 2003 Dec; 1(6):777-87. PubMed ID: 15090224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging role of high-density lipoprotein in the prevention of cardiovascular disease.
    Brousseau ME
    Drug Discov Today; 2005 Aug; 10(16):1095-101. PubMed ID: 16182194
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Niemann-Pick C1 like 1 gene expression is down-regulated by LXR activators in the intestine.
    Duval C; Touche V; Tailleux A; Fruchart JC; Fievet C; Clavey V; Staels B; Lestavel S
    Biochem Biophys Res Commun; 2006 Feb; 340(4):1259-63. PubMed ID: 16414355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation of the liver X receptor protects against hepatic injury in endotoxemia by suppressing Kupffer cell activation.
    Wang YY; Dahle MK; Agren J; Myhre AE; Reinholt FP; Foster SJ; Collins JL; Thiemermann C; Aasen AO; Wang JE
    Shock; 2006 Feb; 25(2):141-6. PubMed ID: 16525352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SAR studies: designing potent and selective LXR agonists.
    Szewczyk JW; Huang S; Chin J; Tian J; Mitnaul L; Rosa RL; Peterson L; Sparrow CP; Adams AD
    Bioorg Med Chem Lett; 2006 Jun; 16(11):3055-60. PubMed ID: 16529931
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potentiation of liver X receptor transcriptional activity by peroxisome-proliferator-activated receptor gamma co-activator 1 alpha.
    Oberkofler H; Schraml E; Krempler F; Patsch W
    Biochem J; 2003 Apr; 371(Pt 1):89-96. PubMed ID: 12470296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib?
    Neeli H; Rader DJ
    Cardiol Clin; 2008 Nov; 26(4):537-46. PubMed ID: 18929230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia.
    Beaven SW; Tontonoz P
    Annu Rev Med; 2006; 57():313-29. PubMed ID: 16409152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular aspects of atherogenesis: new insights and unsolved questions.
    Puddu GM; Cravero E; Arnone G; Muscari A; Puddu P
    J Biomed Sci; 2005 Dec; 12(6):839-53. PubMed ID: 16328782
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cholesteryl ester transfer protein: the controversial relation to atherosclerosis and emerging new biological roles.
    Oliveira HC; de Faria EC
    IUBMB Life; 2011 Apr; 63(4):248-57. PubMed ID: 21488146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.